索拉菲尼联合TACE治疗进展期原发性肝癌疗效及并发症分析  

Analysis of Efficacy and Complications of Sorafenib combined with Transcatheter Arterial Chemoembolization( TACE) for Advanced Hepatocellular Carcinoma

作　　者：谢佳杭[1] 王久惠[1] 

机构地区：[1]四川省肿瘤医院,成都610041

出　　处：《肿瘤预防与治疗》2015年第3期152-154,共3页Journal of Cancer Control And Treatment

摘　　要：目的:探讨索拉菲尼(Sorafenib)联合TACE(肝动脉栓塞化疗)治疗进展期原发性肝癌的疗效及并发症。方法:2008年9月至2010年12月我院收治的进展期原发性肝癌患者83例,随机分为治疗组43例和对照组40例。治疗组患者在行TACE术后服用索拉菲尼;对照组患者只接受TACE术。治疗后对所有患者进行长期随访,分析其临床资料。结果:治疗组总有效率76.7%,对照组总有效率55.0%,两组差异有统计学意义(P<0.05)。治疗组1年、2年、3年的生存率分别为74.4%、44.2%、14.0%,对照组分别为52.5%、32.5%、10.0%,两组患者1年生存率差异有统计学意义(P<0.05),2年、3年生存率差异无统计学意义(P>0.05)。两组患者均未发生严重并发症,治疗组皮肤反应、腹泻、高血压等并发症与对照组相比,差异有统计学意义(P<0.05),绝大多数患者对并发症可耐受,且经治疗后症状缓解。结论:索拉菲尼联合TACE治疗进展期原发性肝癌具有较好的疗效,可延长生存期,且患者对并发症耐受性好,值得临床推广。Objective： To investigate and analyze the efficacy and complications in the treatment of advanced hep- atocellular carcinoma using Sorafenib combined with transcatheter arterial chemoembolization （TACE）. Methods： Eighty- three patients with advanced hepatocellular carcinoma were treated in our hospital from September 2008 to December 2010. All patients were randomly divided into treatment group（43 cases） and control group （40 cases）. In treatment group,pa- tients received the therapy of Sorafenib after the treatment of TACE while in the control group patients only underwent TA- CE. Long-term follow-up was carried out after the treatment and clinical data were analyzed. Results： The total effective rate was 76.7% in treatment group and 55.0% in control group. The efficacy between two groups had statistically signifi- cant difference（P 〈 0.05）. The 1, 2, 3 year survival rate were 74.4% , 44.2% and 14.0% in treatment group and 52. 5%, 32.5% and 10.0% in control group,respectively. The difference of 1 year survival rate between two groups was sig- nificantly different （P 〈 0.05 ） while no significant difference was observed in 2 and 3 year survival rate between these two groups （P 〉 0.05）. None of the patients had severe complications. The incidence of skin reaction, diarrhea and hyperten- sion in treatment group were significantly higher that those in control group （ P 〈 0.05 ）. The complications were endurable in most patients and could get relieved after corresponding treatment. Conclusion： Sorafenib combined with TACE in the treatment for advanced hepatocellular carcinoma could prolong survival time obviously with good efficacy. It is well tolerable in patients and worthy of clinical promotion.

关 键 词：索拉菲尼 肝动脉化疗栓塞 疗效 并发症 

分 类 号：R735.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]